Filing Details
- Accession Number:
- 0001209191-20-057126
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-11-05 16:16:00
- Reporting Period:
- 2020-11-03
- Accepted Time:
- 2020-11-05 16:16:00
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557290 | A Stuart Arbuckle | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp, Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-11-03 | 1,553 | $86.52 | 36,732 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-11-03 | 487 | $210.56 | 36,245 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-03 | 487 | $211.54 | 35,758 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-03 | 245 | $212.38 | 35,513 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-03 | 334 | $214.13 | 35,179 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-11-03 | 1,553 | $0.00 | 1,553 | $86.52 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 1,554 | 2027-02-02 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 140 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $210.56 (range $210.00 to $210.97).
- Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $211.54 (range $211.00 to $211.93).
- Open market sales reported on this line occurred at a weighted average price of $212.38 (range $212.18 to $212.63).
- Open market sales reported on this line occurred at a weighted average price of $214.13 (range $213.89 to $214.60).
- The option vests in 16 quarterly installments from 02/03/2017.
Billionaire Hedge Funds
